

03 CO

**TRANSMITTAL LETTER
(General - Patent Pending)**Docket No.
11375ZIn Re Application Of: **Andrea M. Douglas, et al.**Serial No.
09/819,097Filing Date
March 5, 2001Examiner
UnassignedGroup Art Unit
Unassigned**Title: CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER****TO THE ASSISTANT COMMISSIONER FOR PATENTS:**

Transmitted herewith is:

Response to the Notice to Comply dated October 2, 2001;
Copy of the Notice to Comply;
Paper Copy of Sequence Listing;
Diskette containing computer readable copies of Sequence Listing; and
Statement Under 37 CFR 1.821(f)

in the above identified application.


- No additional fee is required.
 A check in the amount of _____ is attached.
 The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below. A duplicate copy of this sheet is enclosed.
 Charge the amount of _____
 Credit any overpayment.
 Charge any additional fee required.


Signature

Leopold Presser
Registration No. 19,827
SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

Dated: **Dec. 3, 2001 (Monday)**

I certify that this document and fee is being deposited on 12/3/01 (Mon) with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


*Signature of Person Mailing Correspondence***Mishelle Mustafa***Typed or Printed Name of Person Mailing Correspondence***FSD/PIB/JAM:sf**

CC:



#6

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Andrea M. Douglas, et al.

Examiner: Unassigned

Serial No.: 09/819,097

Art Unit: Unassigned

Filed: March 5, 2001

Docket: 11375z

For: CYTOKINES AND THEIR USE
IN TREATMENT AND/OR PROPHYLAXIS
OF BREAST CANCER

Dated: December 3, 2001 (Monday)

Assistant Commissioner for Patents
Washington, DC 20231

Response to Notice to Comply under 37 C.F.R. §1.821


Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated October 2, 2001 and in accordance with the provisions in 37 C.F.R. §1.821, Applicants submit herewith an initial paper and an initial computer readable copy of the Sequence Listing, along with a Statement Under 37 C.F.R. §1.821(f), stating that these copies are identical. A copy of the

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on December 3, 2001 (Monday).

Dated: December 3, 2001 (Monday)


Michelle Mustafa

Notice to Comply is also enclosed. Applicants respectfully submit that the content of the initial paper and initial computer copies of the sequence listing do not introduce new matter.

Respectfully submitted,



The image shows a handwritten signature in black ink, which appears to be "Leopold Presser".

Leopold Presser
Registration No. 19,827

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

FSD/PIB/JAM:sf



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/819,097	03/05/2001	Andrea Margaret Douglas	I1375Z

CONFIRMATION NO. 6127
FORMALITIES LETTER



OC00000006830968

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, NY 11530

Date Mailed: 10/02/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*


Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE